Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
The Phase 1b/2 trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 administered orally and daily, combined with pembrolizumab (KEYTRUDA®), in men with tNEPC.